Navigation Links
FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in Baltimore
Date:3/24/2008

FAIRFAX, Va., March 24 /PRNewswire-USNewswire/ -- The Food Allergy & Anaphylaxis Network (FAAN) will hold its 15th annual Food Allergy Conference in Baltimore, Md., on March 29, 2008. Many families struggle with how best to manage food allergies in their lives. Whether attendees have been living with food allergies for years or are dealing with a new diagnosis, this conference will help.

Conference attendees will learn tips and strategies for living better while managing food allergies. Topics will include causes and symptoms of food-allergic reactions, how food allergies should be diagnosed, strategies for avoiding reactions, how and when to use epinephrine, tips for managing food allergies in schools, ways to prepare a child to manage food allergies, and the latest news on food allergy research.

"There is no cure for food allergy today," said Anne Munoz-Furlong, FAAN Founder and CEO. "Until there is a cure, education is the key to avoiding a reaction. This unique conference brings together hundreds of individuals for a full day of the latest information on living with food allergies."

Anyone who has a food allergy or takes care of someone with a food allergy will benefit from attending. In particular, parents, grandparents, and relatives of children with food allergies, as well as health professionals, registered dietitians, caregivers, child care providers, and school staff, will find the sessions informative.

The Baltimore conference will feature Robert A. Wood, M.D. He is a professor of pediatrics and international health and the director of pediatric allergy and immunology at Johns Hopkins University School of Medicine, as well as the author of Food Allergies for Dummies.

There are even special sessions for teens (ages 11 and up) and nurses at the conference. The teen lunch session will include discussion topics such as school, dating, traveling, and dining out. A concurrent session for parents of teens will
'/>"/>

SOURCE Food Allergy & Anaphylaxis Network
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Naked Juice Brings Consumers Happiness by the Billions With First 100% Juice Smoothie Containing Probiotics
2. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
3. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
4. PSI Brings its Pioneering Efforts to a Close
5. Serta Brings Sweet Dreams and a Special Delivery to Deserving Women
6. Eclipsys User Network Brings Eclipsys Clients Together to Share Outcome Improvement Strategies
7. Governor Rendell Brings Tour to Insure to Scranton and Urges Passage of Plan to Give Access to Affordable Health Insurance
8. New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs
9. IncentOnes Sue Lewis brings "The Art and Science of Incentive Management" to AHIP Business Forum
10. American Diabetes Month(R) Brings Awareness to Growing Health Care Crisis
11. Maine Natural Health Company Brings Omega-3 Benefits to Pets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ... of Hematology meeting Dec. 7, 2009, in New Orleans. ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/5/2009)... three-drug combination has shown in a phase 1/2 ... in the treatment of patients newly diagnosed with multiple ... marrow, say researchers from Dana-Farber Cancer Institute. , Partial ... 66 patients treated with the drug combination in the ... partial response rate" in the phase 2 population, reports ...
(Date:12/5/2009)... --In Youngest Babies, This Type of Blood Cancer Is ... Dec. 5 Pediatric oncologists have identified specific genes, ... drive an often-fatal form of leukemia in infants. By ... better predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... healthcare real estate company providing ... hospitals and physicians ... CHARLOTTE, N.C., Jan. 23 Cogdell Spencer Inc.,(NYSE: ... agreement,to acquire 100 percent of the stock of Marshall Erdman ...
... [Brown University] When faced with even a ... fewer women receive these potentially life-saving breast cancer ... University and Harvard Medical School researchers. , In ... insurance co-payments and mammography rates, researchers found that ...
... 23 Pennsylvania,AFL-CIO President William George and Secretary ... decisions by,Representatives John Peterson, Joseph Pitts, and William ... millions of children in,families hit hardest by our ... in the face of a severe economic downturn,Representatives ...
... Jan. 23 Johnson & Johnson,Pharmaceutical Research & ... Drug Application (NDA) to the U.S. Food and ... an investigational oral analgesic for the relief of ... American Pain Foundation, more than 25 million,Americans experience ...
... Jan. 23 Boston Scientific (NYSE: BSX ),today ... Chief,Medical and Scientific Officer, on an article in the ... and Drug-Eluting Stents for,Off-Label Indications.", "The analysis from ... in today,s New England Journal of Medicine is the ...
... went five years without anti-rejection drugs , , WEDNESDAY, ... transplant recipients to stop taking powerful immunosuppressive drugs are ... in the development of the transplant field is to ... the lifesaving benefit of the transplant without the costs ...
Other Medicine News:Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 2Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 3Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 4Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 5Health News:Health insurance co-payments deter mammography use 2Health News:Health insurance co-payments deter mammography use 3Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Boston Scientific Comments on New England Journal of Medicine Article 2Health News:Boston Scientific Comments on New England Journal of Medicine Article 3Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3
(Date:12/4/2009)... N.Y., Dec. 4 Bayer Diabetes Care today announced the ... Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the ... the country. The grand prize is an in-person meeting today ... 1 diabetes like Nick, are: Caleb, age 6, from Danbury, ...
(Date:12/4/2009)... AZN ) today announced that the US Food ... (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment ... SEROQUEL XR is the only medication in its class ... disorder as adjunctive therapy and acute depressive episodes associated ...
(Date:12/3/2009)... Mass., Dec. 3 Allen Medical Systems, a subsidiary ... today announced the launch of its new Allen Amatech(TM) ... . ,, The website reinforces the Allen ... the new product catalog, with detailed descriptions and design ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 1Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5
... Sanofi-aventis,announced that the U.S. Food and Drug ... in combination with cisplatin,and 5-fluorouracil for induction ... the head and neck (SCCHN) before patients ... its approval on the results of the ...
... AppyScore(TM), the First Blood-based Screen / Triage Test for Human,Appendicitis, ... ... Sensitivity Level of 98%., CASTLE ROCK, Colo., Sept. ... bio-pharmaceutical company dedicated to the,development of novel drugs and diagnostics ...
Other Medicine Technology:Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 2Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 3Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 4AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 2AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 3AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 4AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 5AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 6AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 7AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 8AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 9
Used for complex diagnostic and interventional procedures....
... St. Jude Medical offers a ... for use with percutaneous catheter ... of intravascular catheters. Our diagnostic ... lengths and incorporate a proprietary ...
... VISION Coronary Stent System is Guidant's first ... stents. Cobalt chromium is stronger and more ... chromium stent can have similar strength and ... with struts that are only .0032" thick. ...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: